Scarica l'app Stockscreener
3.14
0.32%
0.01
Dopo l'orario di chiusura:
2.65
-0.49
-15.61%
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Rev - GuruFocus
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
Lantern Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bios funds report 4.48% Lantern Pharma (NASDAQ: LTRN) stake - Stock Titan
Lantern Pharma (NASDAQ: LTRN) cuts R&D, advances oncology pipeline and AI spin-out - Stock Titan
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout - Stock Titan
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - New Castle News
Lantern Pharma Releases Q1 2025 Financial Results - AlphaStreet
Lantern Pharma Announces $9.25 Million Registered Direct Offering and Plans for Independent AI Entity with withZeta.ai 1 - Minichart
Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph - GuruFocus
Lantern Pharma raises capital, plans AI platform spinoff - TipRanks
Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw - TradingView
Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out - Stock Titan
Lantern Pharma closes $4.4M registered direct offering - Investing.com
Lantern Pharma closes $4.4M registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma (LTRN) director buys shares and long-dated warrants - Stock Titan
Lantern Pharma (LTRN) director adds shares and long-dated stock warrants - Stock Titan
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Business Wire
Lantern Pharma (NASDAQ: LTRN) sells 1.45M shares, pre-funded warrants included - Stock Titan
Lantern Pharma Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Lantern Pharma raises $4.4M in registered direct offering - Investing.com UK
Lantern Pharma Inc. announces up to $9.25 million registered direct offering with existing holders and a single institutional investor - marketscreener.com
Lantern Pharma raises $4.4M in registered direct offering By Investing.com - Investing.com Nigeria
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - marketscreener.com
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - BioSpace
Lantern Pharma (LTRN.US) will release its earnings report after the market closes on May 15. - Moomoo
Press Release: Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - Moomoo
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08Wall Street Picks - newser.com
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
Lantern Pharma Inc. Unveils Roadmap for Withzeta.Ai with Launch of Zetaswarm and Zetaomics - marketscreener.com
Lantern starts selling its oncology AI platform, maps swarm upgrade - Stock Titan
Lantern Pharma Inc. 2025 Annual Report Amendment – Executive Compensation, Corporate Governance, and Audit Committee Details - Minichart
Lantern Pharma (NASDAQ: LTRN) details pay, ownership, options - Stock Titan
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery - MEXC Exchange
Lantern Pharma (LTRN) Introduces Advanced Molecular Intelligence Platform - GuruFocus
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Glob - Business Wire
Lantern receives FDA clearance for paediatric STAR-001 CNS trial - MSN
Lantern Pharma Inc (LTRN) Stock Price & 30 Year Financial Data - GuruFocus
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - ChartMill
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - ACCESS Newswire
Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - marketscreener.com
Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.aiA Platform to Conquer Rare Cancers - Palestineherald.com
Lantern Pharma to Debut Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut - marketscreener.com
Lantern Pharma Inc. Debuts Public Demonstration of withZeta.ai Platform - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lake Street Maintains Lantern Pharma(LTRN.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Lantern Pharma schedules FDA meeting on lung cancer trial changes By Investing.com - Investing.com Australia
Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial - TipRanks
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):